|
INCREASED CHANCES OF PROLONGED QT INTERVAL
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
FLUCONAZOLE INCREASES SERUM PLASMA CONCENTRATION OF THE DRUG
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
INCREASED SEDATIVE EFFECT
|
ITRACONAZOLE REDUCES THE DRUG METABOLISM HENCE SERUM LEVELS ARE INCREASED
|
ERYTHROMYCIN INCREASES PLASMA CONCENTRATION OF THE DRUG DUE TO REDUCED CLEARANCE
|
THIORIDAZINE MAY INCREASE ORAL CLEARANCE OF THE DRUG
|
QUETIAPINE REDUCED ORAL CLEARANCE OF THE DRUG
|